Open AccessSafety of Once-Daily Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol in Japanese Patients with Asthma: A Long-Term (52-Week) Phase III Open-Label Study
Author(s) -
Soichiro Hozawa,
Hiroyuki Ohbayashi,
Michiko Tsuchiya,
Yu Hara,
Laurie A. Lee,
Takashi Nakayama,
Jun Tamaoki,
Andrew Fowler,
Takanobu Nishi
Publication year - 2021
Publication title -
journal of asthma and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.162
H-Index - 30
ISSN - 1178-6965
DOI - 10.2147/jaa.s305918
Subject(s) - medicine , fluticasone propionate , adverse effect , clinical endpoint , asthma , b2 receptor , lama , population , inhaler , indacaterol , dry powder inhaler , randomized controlled trial , copd , bronchodilator , bradykinin , receptor , environmental health
The pivotal CAPTAIN study reported a favorable safety profile with once-daily inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β 2 -agonist (ICS/LAMA/LABA) triple combination of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) in patients with inadequately controlled asthma, some of whom were Japanese. Here, we evaluate the long-term (52 weeks) safety of FF/UMEC/VI in Japanese patients with asthma.